Biogen Inc.(BIIB)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
BIIB | 35.92 B | 43.18x | 3.40% | 8.32% | $5.63 | 4.58% | 0.44x | 0.00% | $240.99 | $138.00 |
REGN | 81.67 B | 19.97x | 16.70% | 27.87% | $40.44 | 14.04% | 0.09x | 0.47% | $859.34 | $569.83 |
950200.KQ | 57.23 B | - | 13.30% | -2.62% | - | -10.39% | 0.57x | - | $4690.00 | $2380.00 |
RVMD | 42.13 B | - | - | 0.00% | -$8.87 | -79.09% | 0.46x | 0.00% | $224.31 | $52.48 |
ALNY | 30.87 B | 38.91x | 66.90% | 16.13% | $5.93 | 96.56% | 2.21x | 0.00% | $495.55 | $197.81 |
Peer Valuation & Performance Analysis
Peer group analysis for Biogen Inc. (BIIB) compared to its primary competitors (including REGN, 950200.KQ, RVMD) reveals distinct metrics. BIIB trades at a valuation premium compared to its competitors, with a P/E ratio of 43.2x versus the peer average of 12.2x (representing a 253% premium). This indicates that the market expects superior growth or commands a quality premium for BIIB. In terms of growth, BIIB's revenue growth of 3.4% lags behind the peer average of 32.3%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of 8.3% is below the peer average of 10.3%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• BIIB ranks #3 in P/E ratio, #4 in revenue growth, and #3 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $236.79 | $244.65 | $236.24 | $243.10 | 1,491,975 | +4.12% |
| 2026-10-19 | $231.81 | $236.00 | $231.04 | $233.48 | 949,700 | +0.36% |
| 2026-10-16 | $235.75 | $236.87 | $232.36 | $232.65 | 1,462,600 | -1.15% |
| 2026-10-15 | $236.46 | $240.99 | $235.22 | $235.35 | 1,572,400 | +1.08% |
| 2026-10-14 | $228.99 | $234.20 | $228.00 | $232.83 | 1,947,100 | +1.72% |
| 2026-10-13 | $230.34 | $231.04 | $226.71 | $228.90 | 1,049,100 | -0.22% |
| 2026-10-12 | $233.98 | $238.24 | $229.00 | $229.41 | 1,461,700 | +1.64% |
| 2026-10-09 | $220.62 | $227.20 | $219.23 | $225.71 | 815,000 | +3.33% |
| 2026-10-08 | $220.15 | $223.09 | $215.73 | $218.43 | 1,339,000 | -1.67% |
| 2026-10-07 | $222.93 | $228.00 | $221.40 | $222.15 | 1,298,100 | -0.33% |
| 2026-10-06 | $224.53 | $225.97 | $218.00 | $222.89 | 1,008,100 | -0.31% |
| 2026-10-05 | $219.90 | $223.85 | $218.22 | $223.59 | 951,300 | +1.69% |
| 2026-10-02 | $222.98 | $224.08 | $219.81 | $219.88 | 779,900 | -1.32% |
| 2026-10-01 | $225.50 | $228.31 | $222.50 | $222.82 | 1,755,300 | -1.35% |
| 2026-09-30 | $227.23 | $229.36 | $225.51 | $225.88 | 1,553,300 | -0.52% |
Explore More Analysis for BIIB
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.